Request a Demo
844-SOFTVUE
News
News Categories
Recent News > Team News
![]()
Her breast imaging center leadership will be instrumental in accelerating SoftVue’s adoption trajectory
Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Tomographic Ultrasound, today announced that Elise Berman, M.D., has joined the company as medical director.
Dr. Berman comes to Delphinus with a stellar track record that includes establishing, growing and leading one of the Washington D.C. area’s premier breast imaging practices. For 22 years at Fairfax Radiological Consultants, Dr. Berman served in multiple roles including medical director, breast imaging division chief, director of breast MRI, and was a long-standing member of the Executive Committee. As a medical leader of the group, Dr. Berman implemented numerous programs to improve quality, patient experience, and efficiency. She expanded breast imaging services and oversaw significant increases in overall breast imaging volume, added new breast imaging sites, and built the largest and most highly regarded breast imaging team in the region. Outside of her practice, Dr. Berman serves on the board of the Brem Foundation to Defeat Breast Cancer and was part of the ACS NBCRT Risk Reduction, Screening, and Early Detection Workgroup. In addition, Dr. Berman was named “Top Doctor” and “Best of the Best” in her specialty by her peers.
“There is no group more familiar with the struggles of women with dense breasts than those who care for them, and Dr. Berman has had intimate experience with this patient population throughout her career,” said Delphinus CEO, Scott White. “We are excited to tap her knowledge and insights to ensure we address not only the needs of patients, but also providers at breast imaging centers with whom we work.”
SoftVue, a tomographic breast ultrasound system for screening dense breasts, is approved by the FDA and when paired with mammography, has been shown to identify up to 20 percent more cancers while also reducing false positives and decreasing unnecessary call-backs and biopsies in women with dense breasts. SoftVue provides a new annual screening solution for this population and is the only ultrasound-based breast imaging system that is approved for same day screening as mammography.
“I’ve spent most of my career understanding and developing breast imaging programs, including centers of excellence, and have become well-versed in how an imaging department functions and operates at maximum capability and efficiency,” said Dr. Berman. “I look forward to working with the team at Delphinus to advise and lead the implementation of SoftVue, a groundbreaking breast imaging system that addresses the needs of the large number of women in our country who have dense breasts. I am thrilled to have the opportunity to help this patient population, who have a higher risk of breast cancer, and whose mammograms are harder to interpret for cancer, because of their breast density.”
Delphinus Adds Dr. Elise Berman as New Medical Director to Growing Executive Team
June 18, 2024
Delphinus Adds Dr. Elise Berman as New Medical Director to Growing Executive Team
Her breast imaging center leadership will be instrumental in accelerating SoftVue’s adoption trajectory
Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Tomographic Ultrasound, today announced that Elise Berman, M.D., has joined the company as medical director.
Dr. Berman comes to Delphinus with a stellar track record that includes establishing, growing and leading one of the Washington D.C. area’s premier breast imaging practices. For 22 years at Fairfax Radiological Consultants, Dr. Berman served in multiple roles including medical director, breast imaging division chief, director of breast MRI, and was a long-standing member of the Executive Committee. As a medical leader of the group, Dr. Berman implemented numerous programs to improve quality, patient experience, and efficiency. She expanded breast imaging services and oversaw significant increases in overall breast imaging volume, added new breast imaging sites, and built the largest and most highly regarded breast imaging team in the region. Outside of her practice, Dr. Berman serves on the board of the Brem Foundation to Defeat Breast Cancer and was part of the ACS NBCRT Risk Reduction, Screening, and Early Detection Workgroup. In addition, Dr. Berman was named “Top Doctor” and “Best of the Best” in her specialty by her peers.
“There is no group more familiar with the struggles of women with dense breasts than those who care for them, and Dr. Berman has had intimate experience with this patient population throughout her career,” said Delphinus CEO, Scott White. “We are excited to tap her knowledge and insights to ensure we address not only the needs of patients, but also providers at breast imaging centers with whom we work.”
SoftVue, a tomographic breast ultrasound system for screening dense breasts, is approved by the FDA and when paired with mammography, has been shown to identify up to 20 percent more cancers while also reducing false positives and decreasing unnecessary call-backs and biopsies in women with dense breasts. SoftVue provides a new annual screening solution for this population and is the only ultrasound-based breast imaging system that is approved for same day screening as mammography.
“I’ve spent most of my career understanding and developing breast imaging programs, including centers of excellence, and have become well-versed in how an imaging department functions and operates at maximum capability and efficiency,” said Dr. Berman. “I look forward to working with the team at Delphinus to advise and lead the implementation of SoftVue, a groundbreaking breast imaging system that addresses the needs of the large number of women in our country who have dense breasts. I am thrilled to have the opportunity to help this patient population, who have a higher risk of breast cancer, and whose mammograms are harder to interpret for cancer, because of their breast density.”